FDA approves first ophthalmic spray for mydriasis

Mydcombi ophthalmic spray, a fixed-dose combo of tropicamide and phenylephrine hydrochloride, is indicated for inducing mydriasis for diagnostic procedures and in conditions requiring short term pupil dilation. The most common adverse reactions include transient blurred vision, reduced visual acuity, photophobia, superficial punctate keratitis, and mild eye discomfort.